Semaglutide and belly fat: what the before and after evidence actually shows

Does semaglutide actually reduce belly fat, or just weight overall?

This is a question our prescribers hear most weeks, and the honest answer has two parts. Semaglutide does not selectively dissolve abdominal fat. The medicine works by activating GLP-1 receptors in the brain and gut, which reduces appetite, slows the rate at which food leaves the stomach, and shifts the energy equation over weeks and months. The result is a sustained calorie deficit that leads to fat loss across the body.

That said, the body tends to draw down visceral fat (the deeper abdominal fat wrapped around organs) relatively early in a meaningful deficit, partly because visceral fat is metabolically active and releases energy more readily than subcutaneous (under-skin) fat. This is why waist circumference reductions are consistently reported in trial data, even when the headline figure is whole-body weight. It is not magic targeted at the belly; it is that a real deficit, held over time, tends to show up there.

The STEP 1 trial, published in the New England Journal of Medicine, randomised nearly 2,000 adults without diabetes to either semaglutide 2.4mg weekly or placebo alongside lifestyle changes, over 68 weeks. The semaglutide group lost around 15% of body weight on average. Waist circumference fell substantially alongside total weight. Those figures are averages, though, the real range in individual results is wide, and factors including starting weight, diet quality and activity level all shift where any one person lands.

You can read broader context on semaglutide before and after results if you want a fuller picture of how outcomes differ across starting points.

The before-and-after timeline: when belly fat changes typically become visible

Semaglutide is titrated gradually: the dose begins at 0.25mg weekly and rises in roughly monthly steps to a 2.4mg maintenance dose. That titration exists to let the body adjust and to reduce the intensity of gastrointestinal side effects. During the first four to eight weeks, dose escalation is the main event, most people are not yet at a therapeutic dose, and visible change is usually modest.

From around weeks 8 to 12, appetite suppression is more established, food intake tends to fall more reliably, and many people begin to notice clothes fitting differently. Weeks 12 to 24 are often when the before-and-after contrast first becomes meaningful for someone looking in a mirror. Abdominal measurements tend to track with overall weight loss across this window rather than preceding it or lagging behind it significantly.

Progress is rarely linear. A plateau at weeks 16 to 24 is common and does not signal the medicine has stopped working. The timeline of how long Wegovy takes to work covers this in more detail, including why patience in the first two months is genuinely warranted.

For people curious about the very early window, what happens at one month on semaglutide sets realistic expectations for that phase. And if six weeks is the reference point you're working from, the evidence around six-week belly changes on semaglutide is worth reading carefully, the picture at six weeks is real but early.

What shapes how much abdominal fat you lose, and how fast

Starting BMI, metabolic health, sleep quality, alcohol intake and physical activity all influence how fat loss distributes and how quickly it proceeds on semaglutide. People with a higher proportion of visceral fat at the outset (which is more common in men, in people with type 2 diabetes or prediabetes, and in people with higher BMIs) often see proportionally larger waist reductions relative to scale weight early on. Men's before and after experiences on semaglutide often reflect this, because abdominal fat distribution is different; the semaglutide results in men page covers that specifically.

Diet composition on treatment also matters. Adequate protein (which helps preserve muscle while fat is lost), fibre, and staying well-hydrated all support the process. Semaglutide slows gastric emptying, so digestion timing on Wegovy is worth understanding, particularly around meals, it affects both comfort and appetite signals.

One practical point worth knowing: because semaglutide reduces appetite substantially, eating enough protein becomes a conscious effort for some people. A prescriber can advise on this; it is not territory to navigate alone. The Wegovy treatment overview covers what clinical support looks like alongside the medicine itself.

For those thinking about cost alongside all of this, the Wegovy cost context page lays out what the UK private market looks like and what a legitimate price actually covers, useful reading before making any decision.

Making the decision: what the evidence is and is not telling you

Before and after images circulate widely online, and some are striking. A few things worth holding onto when you see them. First, photographs are selected, the dramatic results get shared, the modest ones rarely do. Second, 68 weeks is over a year; the most visible changes in most cases accumulate over that full period. Third, semaglutide is licensed and recommended by NICE (TA875) for adults meeting specific BMI and health criteria, it is a clinically evaluated medicine with a real evidence base, not a shortcut.

The question this page's keyword is really asking is: will this work for me, on my belly, in a realistic timeframe? The clinical evidence says yes, it very likely reduces abdominal fat as part of overall weight loss, at a pace that becomes meaningful between three and six months for most people. The decision about whether to start, which medicine suits your health picture, and what dose is appropriate is a clinical one. If you'd like that conversation, starting a free consultation is the first step, a GPhC-registered prescriber reads every assessment personally, the same day.